Integrated Diagnostics for Prostate Cancer

Informacje na temat projektu

ID-PROSTATE

Identyfikator umowy o grant: 961205

DOI

10.3030/961205

Realizacja projektu zakończyła się 18 Lutego 2022

Data podpisania przez KE 14 Lipca 2020

Data rozpoczęcia 1 Lipca 2020

Data zakończenia 30 Czerwca 2022

Finansowanie w ramach

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Koszt całkowity

€ 3 000 531,25

Wkład UE

€ 2 100 371,88

Koordynowany przez

QUANTIB BV
Netherlands

Periodic Reporting for period 2 - ID-PROSTATE (Integrated Diagnostics for Prostate Cancer)

Okres sprawozdawczy: 2021-07-01 do 2022-06-30

Podsumowanie kontekstu i ogólnych celów projektu

Prostate cancer is the most common type of cancer in men and their second leading cause of death; however, it is highly treatable in the early stages. Recent studies and clinical trials have demonstrated the efficiency of prostate MRI in early diagnosis, with 5 times less missed cancer cases and 25 % fewer biopsies. Care standards now recommend MRI prior to every biopsy, leading to an increased demand for prostate MRI scans. Conventional radiology reading capacity cannot keep pace with the demand. Quantib BV (Netherlands) developed an AI-enhanced integrated diagnostic solution for the detection of potential tumors and workflow optimization involving urologists, radiologists and pathologists. The current EU-funded ID-PROSTATE project allows further improvement and acceleration focusing on product commercialization.

Prace wykonane od początku projektu do końca okresu sprawozdawczego oraz najważniejsze dotychczasowe rezultaty

An initial version of Quantib Prostate was completed and certified for clinical use in both the United States (FDA clearance) as well as within the EU (CE-certification). This initial version is in use across a network of sites leading to workflow / UX improvements being released rapidly. In addition this initial version has provided critical insight into the needs for the expanded version featuring additional AI-components which has now also been submitted for review to the FDA.

Innowacyjność oraz oczekiwany potencjalny wpływ (w tym dotychczasowe znaczenie społeczno-gospodarcze i szersze implikacje społeczne projektu)

We expect the expanded version will deliver the ability for clinicians to report on prostate MR at speed beyond the current state-of-the-art. This will impact the adoption and high-quality and cost-effective use of MRI in early diagnosis of prostate cancer and will thus impact men across Europe and the United States.

banner-logo-psa-not-filled.png